Lilly vs. Novo Nordisk: The Obesity Drug War, Explained

For most of the last decade, Novo Nordisk was the weight-loss drug industry. It invented semaglutide, launched Ozempic in 2017 and Wegovy in 2021, and spent years as the only company with a product that reliably worked.

That is no longer the situation. By September 2026, IQVIA prescription data cited by Citi analysts put Eli Lilly’s tirzepatide at nearly 57% of the total US GLP-1 market, up from about 49.5% a year earlier, while Novo Nordisk’s semaglutide held roughly flat at 37% [1]. Lilly’s chief executive told CNBC in February 2026 that the company was the market leader in both diabetes and obesity [4].

But “Lilly is winning” is too simple. In the fastest-growing part of the market, weight-loss pills, Novo Nordisk is running roughly four times Lilly’s prescription volume [1]. This is a rivalry with different scoreboards, and the one you care about depends on what you need.

Who is actually ahead right now?

Three numbers tell most of the story.

Prescription share. In the obesity segment, the split between Lilly’s Zepbound and Novo’s Wegovy has hovered around 60/40 in Lilly’s favor through most of 2026 [1]. Among injectable incretin drugs, Lilly said in August 2026 that its products were drawing three out of every four new patient starts [3].

Revenue. In the second quarter of 2026, Lilly reported worldwide revenue of $23.0 billion, up 48% year over year, driven by a 60% increase in volume partly offset by a 13% decrease in realized prices. Mounjaro alone brought in $9.9 billion, up 91%, and Zepbound $4.9 billion, up 46% [2]. In the same quarter, Novo Nordisk reported net sales of DKK 78.5 billion, up 2% in Danish kroner and 3% at constant exchange rates, with adjusted sales up 7% at constant exchange rates and adjusted operating profit of DKK 33.4 billion [21]. Reported operating profit fell 16% at constant exchange rates, partly because of DKK 6.3 billion in non-cash impairment charges on pipeline assets [21].

Those are very different growth rates, but they are not quite the same measurement: Lilly’s figure is total company revenue in dollars, Novo’s is total company sales in kroner, and currency moves between the two.

Guidance. In February 2026 the two companies gave sharply diverging outlooks: Lilly forecast $80 billion to $83 billion in revenue for the year, above analyst expectations, while Novo Nordisk braced for a sales decline [4]. Lilly later raised its guidance to $85 billion to $87 billion [2]. Novo also raised its outlook in August 2026, but to adjusted sales growth of 0% to -6% at constant exchange rates — an improvement that still describes a shrinking year [21].

The exception is pills, and it is a big one.

Why is Novo winning the pill war?

Novo Nordisk got the Wegovy pill approved on December 22, 2025 and launched it in January 2026 [8]. Lilly got Foundayo approved on April 1, 2026 and launched it a week later [9]. Three months of head start turned out to matter enormously.

By June 2026 Novo said the Wegovy pill had passed 3 million US prescriptions in just over five months, which the company called one of the strongest US pharmaceutical launches by volume on record, and by its August 2026 quarterly report the figure had passed 5 million [21]. By September 2026 it was running about 183,000 prescriptions a week. Foundayo, in the same week, logged about 47,500 [1].

One caveat on all of these figures: they come from IQVIA prescription data cited by Citi and Jefferies, and Novo’s own count is higher. Novo told investors that Wegovy pill weekly prescriptions exceeded 265,000 for the week ending July 17, 2026, against roughly 170,000 in the IQVIA-derived tracker for the same period [21][1]. Company counts and prescription-audit data capture different channels, so treat both as estimates rather than a census.

Three things explain the gap:

1. Brand recognition. “Wegovy” was already a household word. “Foundayo” was a name nobody had heard in April 2026. Lilly executives have said repeatedly that building awareness for a new brand takes time.
2. Insurance coverage. The Wegovy pill had full coverage in its first week. Foundayo did not have coverage from all three major pharmacy benefit managers until CVS Caremark came online on June 1 [1].
3. Measurement. Analysts at Citi and Jefferies have repeatedly flagged that IQVIA data may under-capture telehealth prescriptions, which make up a larger share of Foundayo’s volume. Lilly told analysts that telehealth platforms were generating about 35% of the pill’s early launch volume [1].

Lilly’s second-quarter Foundayo revenue of $98 million worldwide came in below Wall Street consensus and was widely described as a disappointment [2][3]. The gap in new prescriptions is narrower than the gap in total prescriptions, though: a Jefferies note in late August 2026 put Foundayo at 21.5% of new oral obesity prescriptions [1].

How big is the prize they are fighting over?

IQVIA put the global obesity medicines market at $66 billion in list-price sales in 2025 and forecast $92 billion for 2026, with a wide range of $105 billion to $200 billion from 2027 onward [5].

Longer-range forecasts got volatile in 2026. In February, Reuters reported that Goldman Sachs had cut its 2030 estimate to $105 billion from $130 billion, citing steeper price erosion, and that IQVIA had pushed its roughly $130 billion forecast out to 2034 from 2028. The much-quoted $150 billion figure moved from 2030 to 2035 in several models [6]. Then in June, Goldman raised its 2030 number back up to $114 billion, citing faster adoption of oral pills and better affordability [7].

The patient numbers are more stable. A KFF poll fielded in late 2025 found that 12% of US adults were currently taking a GLP-1 drug for weight loss or a chronic condition, and 18% had taken one at some point [17]. Gallup, asking specifically about weight loss, found 11% of adults currently using one in 2026, up from 3% in 2024.

What actually changed the balance of power?

Tirzepatide simply worked better on weight

Tirzepatide activates two receptors, GIP and GLP-1. Semaglutide activates one. In the trials, that translated into more weight loss, and in a head-to-head study of the injections, tirzepatide came out ahead. That is the foundation of Lilly’s lead and no amount of marketing changed it.

Novo Nordisk responded with three products, not one

Novo’s counterattack came in three pieces. The Wegovy pill arrived first. Then Wegovy HD, a 7.2 mg injection, was approved March 19, 2026 under the FDA’s new Commissioner’s National Priority Voucher, on the strength of the STEP UP trial showing 20.7% mean weight loss at 72 weeks with roughly one in three participants losing at least 25% of body weight [10]. Third, CagriSema, a combination of semaglutide with the amylin analog cagrilintide, was filed with the FDA on December 18, 2025 after reporting 22.7% mean weight loss at 68 weeks [11].

Together these narrow the efficacy gap considerably. On the one occasion Novo Nordisk tested the question directly, though, it did not close it. In the open-label Phase 3 REDEFINE 4 trial, 809 adults were randomized to CagriSema or tirzepatide for 84 weeks. On February 23, 2026 Novo reported that CagriSema missed its primary endpoint of non-inferiority: 23.0% mean weight loss against tirzepatide’s 25.5% on the efficacy estimand, and 20.2% against 23.6% counting everyone randomized [25][26].

That is a real result from a real head-to-head trial, which is rare in this field and worth more than the cross-trial comparisons that dominate coverage. It is also one trial, in one population, at one dose of each drug.

Lilly answered with the deepest pipeline in the industry

Lilly’s Phase 3 asset is retatrutide, a triple agonist hitting GIP, GLP-1 and glucagon receptors. In TRIUMPH-1 it produced 28.3% mean weight loss at 80 weeks on the 12 mg dose, and two more Phase 3 trials reported in July 2026. Lilly said it would file with the FDA in the first quarter of 2027 [12]. Behind that sit the amylin analog eloralintide in Phase 3 and the muscle-sparing antibody bimagrumab in Phase 2.

Novo Nordisk restructured

In 2025 Novo Nordisk issued a profit warning, replaced its chief executive, and announced a global cut of about 9,000 roles, roughly 11% of its workforce, targeting about DKK 8 billion ($1.25 billion) in annual savings by the end of 2026 [13]. New CEO Mike Doustdar then made the largest R&D acquisition in the company’s history, agreeing in October 2025 to buy Akero Therapeutics for up to $5.2 billion for a liver disease drug that could pair with Wegovy [14].

What does the rivalry mean for what you pay?

Competition is one reason US prices came down in 2026, but policy was the bigger one.

On November 6, 2025 the White House announced most-favored-nation pricing agreements with both companies. Medicare would pay about $245 per month for GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound, with a $50 patient copay, and both companies agreed to offer discounted cash prices through a government platform, TrumpRx.gov, launched in January 2026 [16]. The Medicare GLP-1 Bridge program went live July 1, 2026 at a $50 monthly copay for eligible Part D beneficiaries, running through the end of 2027 [1].

Self-pay prices moved too, though the headline numbers are all starting doses, and the most-quoted one was itself a policy term rather than a competitive move: under the November 2025 agreements, both companies committed to selling starter doses of their oral obesity medicines at $149 a month [16]. Foundayo starts at $149 per month for the 0.8 mg dose through LillyDirect, rising to $299 and then $349 for maintenance doses, with commercially insured patients eligible for as little as $25 per month [9][22]. Novo Nordisk’s Wegovy pill runs $149 per month for 1.5 mg, $199 for 4 mg and $299 for the 9 mg and 25 mg doses through NovoCare Pharmacy [23]. Lilly’s self-pay price for Zepbound starts at $299, and the Wegovy pen is $349 per month for self-pay patients [23].

A further cut is scheduled but has not taken effect. On February 24, 2026 Novo Nordisk said that from January 1, 2027 the US list price of Wegovy, Ozempic and Rybelsus would fall to $675 per month, roughly 50% and 35% reductions for Wegovy and Ozempic [24]. That is the wholesale acquisition cost, not the cash price, so it mainly changes what people with high-deductible or coinsurance plans are billed against rather than the self-pay figures above.

None of these prices is guaranteed to last, and what you personally pay depends on your dose, your plan and which program you qualify for. The access-and-pricing side of this is worth checking directly with the manufacturer before you budget.

Who else is in the fight?

The two-horse framing is already out of date.

Pfizer spent about $10 billion buying Metsera in November 2025, after a public bidding war in which Novo Nordisk made unsolicited counteroffers and Pfizer filed two lawsuits [15]. Pfizer’s lead asset, berobenatide, is a monthly GLP-1 with 10 Phase 3 trials planned for 2026 and a first approval targeted for 2028.

Amgen has MariTide, a monthly injection now in a broad Phase 3 program. Roche built a portfolio by buying Carmot Therapeutics for $2.7 billion and partnering with Zealand Pharma on the amylin analog petrelintide. AstraZeneca moved its oral GLP-1 elecoglipron into Phase 3 and, in January 2026, signed a deal with China’s CSPC Pharmaceutical worth $1.2 billion upfront and up to $18.5 billion in total for eight obesity and diabetes programs [18].

And outside the US, the ground has already shifted. Semaglutide’s Indian patent expired on March 20, 2026, and more than a dozen generic versions launched within days at prices as low as a few hundred rupees per injection. CNBC reported in April 2026 that Lilly lost share in India’s GLP-1 market as generics surged, while Novo Nordisk held steadier after deep price cuts [20].

What this means for you

If you are trying to pick a medication, market share is close to irrelevant. What matters is which drug your insurance covers, which one your provider thinks fits your health history, whether you can tolerate the side effects, and whether you would rather take a pill or an injection. Those are clinical and practical questions, not competitive ones.

Where the rivalry does touch you is in supply, price and choice. More companies chasing the same market means more options in pharmacies, more pressure on list prices, and more manufacturer programs competing for cash-paying customers. It also means faster label expansions, since each company has an incentive to prove its drug does more than the other one’s.

The one thing the rivalry cannot do is tell you what to take. Bring the list of approved options to a healthcare provider, along with your insurance details, and work it out there.

Sources

1. Fierce Pharma, “The Oral GLP-1 Tracker: Novo’s Wegovy pill, Lilly’s Foundayo continue prescription climb” — https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill
2. Eli Lilly, “Lilly reports second-quarter 2026 financial results, raises full-year guidance” — https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full
3. Fierce Pharma, “Lilly’s obesity pill Foundayo ‘disappointed’ in Q2, as injectables continue to boom” — https://www.fiercepharma.com/pharma/while-sales-lillys-obesity-pill-disappointed-q2-injectables-continue-boom
4. CNBC, “Eli Lilly gaining in GLP-1 market over Novo Nordisk” — https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html
5. IQVIA, “The outlook for obesity from 2026 to 2030” — https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030
6. Reuters, “Obesity market sales potential tightens as Novo and Lilly enter new era” — https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-market-sales-potential-tightens-novo-lilly-enter-new-era-2026-02-02
7. ZeroHedge, “Goldman Hikes Obesity Drug Market Forecast As Oral GLP-1s Go Mass Market” — https://www.zerohedge.com/medical/goldman-hikes-obesity-drug-market-forecast-oral-glp-1s-go-mass-market
8. Novo Nordisk, “FDA approves Novo Nordisk’s Wegovy pill” — https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html
9. Eli Lilly, “FDA approves Lilly’s Foundayo (orforglipron)” — https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
10. Novo Nordisk, “FDA approves Novo Nordisk’s new Wegovy HD injection” — https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-new-wegovy-hd-injection-delivering-the-highest-weight-loss-to-date-for-a-wegovy-injection-adding-to-its-already-expansive-clinical-profile-302718982.html
11. Novo Nordisk, “Novo Nordisk files for FDA approval of CagriSema” — https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html
12. Eli Lilly, “Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials” — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
13. Reuters, “Novo Nordisk cuts hit production line jobs at key US plant” — https://www.reuters.com/business/world-at-work/novo-nordisk-cuts-hit-production-line-jobs-key-us-plant-posts-show-2025-10-07
14. Novo Nordisk, “Novo Nordisk to acquire Akero Therapeutics” — https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916433
15. CNBC, “Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits” — https://www.cnbc.com/2025/11/08/metsera-accepts-pfizers-10-billion-bid-in-ongoing-ma-battle.html
16. The White House, Fact Sheet on most-favored-nation pricing agreements — https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients
17. KFF, “Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug” — https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford
18. Reuters, “AstraZeneca strikes deal for up to $18.5 billion to license weight-loss drugs from China’s CSPC” — https://www.reuters.com/business/healthcare-pharmaceuticals/chinas-cspc-pharmaceutical-inks-deal-with-astrazeneca-weight-loss-therapy-2026-01-30/
19. BigGo Finance, “Novo Nordisk CFO Knudsen: Oral Wegovy Drives Market Expansion” — https://finance.biggo.com/news/483d08b39dac86a2
20. CNBC, “India is launching cheap weight-loss drugs, but Novo Nordisk is betting its brands will stay on top” — https://www.cnbc.com/2026/03/23/novo-nordisk-cheap-weight-loss-drugs-india-generic-ozempic-wegovy-semaglutide.html
21. Novo Nordisk, “Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook,” company announcement No 48/2026, August 4, 2026 — https://www.novonordisk.com/news-and-media/news-and-ir-materials.html
22. LillyDirect, Foundayo self-pay pricing — https://www.lilly.com/lillydirect/foundayo
23. NovoCare, Wegovy cost and coverage pricing table — https://www.novocare.com/patient/medicines/wegovy.html
24. Novo Nordisk, “Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus” — https://www.prnewswire.com/news-releases/novo-nordisk-announces-significant-reduction-in-us-list-price-for-wegovy-ozempic-and-rybelsus-semaglutide-medicines-building-on-continued-efforts-to-expand-access-302695705.html
25. HCPLive, “CagriSema Demonstrates Weight Loss, Fails to Achieve Primary Endpoint Compared to Tirzepatide” (REDEFINE 4 headline results, February 23, 2026) — https://www.hcplive.com/view/cagrisema-demonstrates-weight-loss-fails-to-achieve-primary-endpoint-compared-to-tirzepatide
26. MPR, “REDEFINE 4: CagriSema Weight Loss Results Compared With Tirzepatide” — https://www.empr.com/news/redefine-4-cagrisema-weight-loss-results-compared-with-tirzepatide/